Axxcess Wealth Management LLC Has $226,000 Stake in Natera, Inc. (NASDAQ:NTRA)

Axxcess Wealth Management LLC trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA) by 29.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,425 shares of the medical research company’s stock after selling 601 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Natera were worth $226,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the company. Nikko Asset Management Americas Inc. lifted its holdings in shares of Natera by 10.3% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 740,837 shares of the medical research company’s stock valued at $117,274,000 after buying an additional 69,455 shares during the last quarter. Twin Tree Management LP lifted its holdings in shares of Natera by 223.7% during the 4th quarter. Twin Tree Management LP now owns 17,321 shares of the medical research company’s stock valued at $2,742,000 after buying an additional 31,321 shares during the last quarter. Catalyst Funds Management Pty Ltd lifted its holdings in shares of Natera by 179.5% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 18,725 shares of the medical research company’s stock valued at $2,964,000 after buying an additional 12,025 shares during the last quarter. Poinciana Advisors Group LLC acquired a new stake in shares of Natera during the 4th quarter valued at about $279,000. Finally, Parnassus Investments LLC raised its stake in shares of Natera by 11.8% in the 4th quarter. Parnassus Investments LLC now owns 10,331 shares of the medical research company’s stock valued at $1,635,000 after acquiring an additional 1,090 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

NTRA opened at $151.15 on Friday. The stock has a market cap of $20.43 billion, a PE ratio of -85.88 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1 year low of $83.13 and a 1 year high of $183.00. The stock’s 50 day simple moving average is $161.23 and its 200-day simple moving average is $149.75.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on NTRA shares. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research note on Wednesday. Piper Sandler raised their price objective on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. raised their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. BTIG Research reissued a “buy” rating on shares of Natera in a research note on Friday, February 28th. Finally, Sanford C. Bernstein raised their price objective on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $178.12.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 6,000 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total value of $859,740.00. Following the sale, the insider now owns 143,768 shares of the company’s stock, valued at $20,600,516.72. The trade was a 4.01 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gail Boxer Marcus sold 4,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total value of $590,760.00. Following the completion of the sale, the director now directly owns 9,704 shares in the company, valued at approximately $1,433,183.76. This represents a 29.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 307,466 shares of company stock valued at $49,047,655 in the last 90 days. 7.60% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.